Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > REGULATORY
REGULATORY
- CSIMC to Discuss Additional Price Cuts for Long-Listed Drugs
November 28, 2011
- DPJ's Subcommittee for PAL Amendment Begins Deliberations Nov. 28, to Compile Opinion by End-Jan
November 25, 2011
- Obligatory Use of Generics for Welfare Recipients to Be Discussed: Policy Screening
November 25, 2011
- HPB, HSB Issue Notification to Ensure Stable Supplies of Flu Drugs This Season
November 25, 2011
- Experts Call For Establishment of Independent Vaccine Policy Organization
November 25, 2011
- Otsuka to Challenge Grand Champion Santen in Market for Dry Eye Treatments
November 25, 2011
- Policy Screening Committee Proposes Major Cutbacks in Long-Listed Drug Prices, Additional Decreases Possible
November 24, 2011
- Patients’ Copayments for OTC-like Drugs to Be Increased on a Trial Basis: Policy Screening
November 24, 2011
- Council Approves New 10-Year Strategy for Hepatitis Research
November 24, 2011
- MHLW Council Approves Subsidizing Telaprevir Combination Therapy
November 24, 2011
- DPJ WT to Propose New Measures to Promote Generics
November 24, 2011
- Committee on OTC Drugs Recommends SSP’s Vaginal Candidiasis Treatment for Approval
November 24, 2011
- Korosho Issues Notification to Ensure Stable Supplies of Flu Drugs This Season
November 24, 2011
- Korosho’s Council Approves Subsidizing 3-Drug Combination Therapy Including Teraprevir
November 22, 2011
- MHLW Study Group Postpones Decision on Relief System for Victims of Health Damages Due to Anticancer Drugs
November 21, 2011
- After Delay, CSIMC Recommends Listing of Ilaris for Treatment of CAPS
November 21, 2011
- US FDA Revokes Avastin’s Approval for Metastatic Breast Cancer
November 21, 2011
- Former Chuikyo Chairman Prof. Endo Concerned about Increasing Drug Expenditure
November 21, 2011
- CSIMC Subcommittee Approves Special Price Reductions for Combination Drugs
November 18, 2011
- CSIMC Excludes DPC Flat-Sum Reimbursement, Recommends Approval for Reimbursement by Piecework for 5 APIs
November 18, 2011
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…